Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Xiao Wan from Professor Eric O’Neill’s group for her success in obtaining an NC3Rs Training Fellowship for ‘Developing human organotypic perfused bioreactors for physiologically reproducible therapeutic compound screening of a tumour microenvironment’.

Xiao's research at the CRUK/MRC Oxford Institute for Radiation Oncology in the Department of Oncology focuses on developing bioreactors that more accurately recapitulate the tumour microenvironment, including the interplay of tumour and stromal cells, than current in vitro systems, by including perfusion by blood vessels.

In 2017, the National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs) announced seven new fellowships, a commitment of nearly £1.2 million, to support talented early career scientists in the discovery and development of new technologies and approaches to replace, reduce and refine the use of animals in scientific research. The NC3Rs provides two type of fellowships awards: Training Fellowships for researchers with less than three years postdoctoral experience and the intermediate career stage David Sainsbury Fellowships for researchers with two to six years of postdoctoral experience.

Using the funding from the Training Fellowship, Xiao hopes to develop highly interdisciplinary tools for creating artificial tissue in perfusion culture to replicate physiological and pathological processes with less chemical fluctuation and biological stress.

Xiao commented: "The outcome will benefit the oncology research communities, including researchers in Oxford as well as my collaborators in China, by enabling them to test their therapeutics in a better-defined tissue microenvironment compared with petri-dish methods. The techniques optimised by this project will have the potential to replace and reduce the use of animals in the preclinical evaulation of therapeutics, especially those targeting at tissue microenvironment, such as the epigenetic events in cancer development."

Further information about Xiao's project can be found on the NC3Rs website.

Similar stories

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Eileen Parkes secures Clinical Research Career Development Fellowship

Eileen is awarded funding for her research into the tumour microenvironment

MP Anneliese Dodds tours Oxford cancer research

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.